Stockreport

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immu [Read more]